Innogenetics and Takeda enter into License Agreement on Takeda's beta-amyloid antibody patents for Alzheimer's Disease

10-Jun-2004

Gent. Innogenetics announced that Innogenetics and Takeda Chemical Industries, Ltd., Osaka, Japan ("Takeda") have entered into a worldwide licensing agreement by which Innogenetics gains access to Takeda's patent rights for the diagnostic and research use of beta-amyloid antibodies. The financial terms of this agreement were not disclosed.

The abnormal accumulation of beta-amyloid protein in the brain is one of the two pathological hallmarks of Alzheimer's disease, and represents a particularly useful diagnostic marker for the disease.

Innogenetics is one of the pioneers in the development and commercialization of novel biochemical markers (biomarkers) for the early and differential diagnosis of Alzheimer's disease and other neurodegenerative disorders.

"This significant license agreement with Takeda strengthens and complements Innogenetics' position in the field of neurodegenerative biomarkers," added Philippe Archinard, Chief Executive Officer of Innogenetics. "The addition of Takeda's beta-amyloid-related patent rights to our proprietary Tau and phospho-Tau patent portfolios underscores Innogenetics' leadership position in the development and marketing of novel diagnostic tools for better and earlier patient diagnosis, and for accelerated drug development."

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous